CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Tau Therapeutics LLC, a company repositioning and developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that President and CEO Andrew J. Krouse will speak at the World Drug Repositioning Congress in London, England, September 11-13, 2012. Tau Therapeutics is repositioning former hypertension drug, mibefradil dihydrochloride, in its Interlaced Therapy™ method to treat solid tumor cancers.
